PL355667A1 - Pochodne chemiczne i ich zastosowanie jako środkaprzeciw telomerazie - Google Patents

Pochodne chemiczne i ich zastosowanie jako środkaprzeciw telomerazie

Info

Publication number
PL355667A1
PL355667A1 PL00355667A PL35566700A PL355667A1 PL 355667 A1 PL355667 A1 PL 355667A1 PL 00355667 A PL00355667 A PL 00355667A PL 35566700 A PL35566700 A PL 35566700A PL 355667 A1 PL355667 A1 PL 355667A1
Authority
PL
Poland
Prior art keywords
arylamine derivatives
telomerase agent
telomerase
agent
concerns
Prior art date
Application number
PL00355667A
Other languages
English (en)
Inventor
Patrick Mailliet
Jean-Francois Riou
Jean-Louis Mergny
Abdelazize Laoui
Francos Lavelle
Odile Petitgenet
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915031A external-priority patent/FR2801588B1/fr
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of PL355667A1 publication Critical patent/PL355667A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL00355667A 1999-11-29 2000-11-27 Pochodne chemiczne i ich zastosowanie jako środkaprzeciw telomerazie PL355667A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9915031A FR2801588B1 (fr) 1999-11-29 1999-11-29 Derives chimiques et leur application comme agent antitelomerase
FR0010561 2000-08-11

Publications (1)

Publication Number Publication Date
PL355667A1 true PL355667A1 (pl) 2004-05-04

Family

ID=26212577

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355667A PL355667A1 (pl) 1999-11-29 2000-11-27 Pochodne chemiczne i ich zastosowanie jako środkaprzeciw telomerazie

Country Status (27)

Country Link
EP (1) EP1244650B1 (pl)
JP (1) JP2003515604A (pl)
KR (1) KR20020058043A (pl)
CN (1) CN1402722A (pl)
AT (1) ATE243692T1 (pl)
AU (1) AU2179001A (pl)
BG (1) BG106753A (pl)
BR (1) BR0015992A (pl)
CA (1) CA2392507A1 (pl)
CO (1) CO5251431A1 (pl)
CZ (1) CZ20021849A3 (pl)
DE (1) DE60003583T2 (pl)
DK (1) DK1244650T3 (pl)
EA (1) EA200200616A1 (pl)
EE (1) EE200200263A (pl)
ES (1) ES2202206T3 (pl)
HU (1) HUP0204429A2 (pl)
IL (1) IL149402A0 (pl)
MX (1) MXPA02005276A (pl)
NO (1) NO20022528L (pl)
PE (1) PE20010912A1 (pl)
PL (1) PL355667A1 (pl)
PT (1) PT1244650E (pl)
SK (1) SK7402002A3 (pl)
UY (1) UY26456A1 (pl)
WO (1) WO2001040218A1 (pl)
YU (1) YU38102A (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
US6977259B2 (en) 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
AU2001282268A1 (en) * 2000-08-08 2002-02-18 Aventis Pharma S.A. Phenantridine derivatives and their use as anti-telomerase agent
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
FR2821355A1 (fr) * 2001-02-23 2002-08-30 Aventis Pharma Sa Derives chimiques et leur application comme agent antitelomerase
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
FR2822468B1 (fr) * 2001-03-23 2008-06-20 Aventis Pharma Sa Derives chimiques et leur application comme agent anti-telomerase
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2003260472A1 (en) * 2002-09-10 2004-04-30 Pharmacia Italia S.P.A. Substituted pyridine derivatives as antitumor agent
WO2004037808A1 (en) * 2002-10-24 2004-05-06 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
CA2546727C (en) * 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
WO2007049057A2 (en) * 2005-10-28 2007-05-03 Iti Scotland Limited Novel fluorescent dyes and uses thereof
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
KR100761869B1 (ko) * 2006-07-07 2007-10-04 김현기 트리아진 유도체 화합물 및 이를 포함하는 암 치료용조성물
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
JP5325517B2 (ja) * 2007-10-12 2013-10-23 住友化学株式会社 ジベンゾオキセピン化合物の精製方法
JP2009102249A (ja) * 2007-10-22 2009-05-14 Sumitomo Chemical Co Ltd ジベンゾオキセピン化合物の結晶の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
US5770613A (en) * 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6156763A (en) * 1998-02-04 2000-12-05 Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
DE19812879A1 (de) * 1998-03-24 1999-09-30 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine

Also Published As

Publication number Publication date
WO2001040218A1 (fr) 2001-06-07
PE20010912A1 (es) 2001-09-01
ATE243692T1 (de) 2003-07-15
JP2003515604A (ja) 2003-05-07
NO20022528D0 (no) 2002-05-28
BG106753A (bg) 2003-02-28
BR0015992A (pt) 2002-08-06
YU38102A (sh) 2004-12-31
MXPA02005276A (es) 2002-11-07
CA2392507A1 (fr) 2001-06-07
EP1244650B1 (fr) 2003-06-25
UY26456A1 (es) 2001-06-29
CZ20021849A3 (cs) 2002-08-14
DK1244650T3 (da) 2003-10-20
EE200200263A (et) 2003-06-16
DE60003583T2 (de) 2004-05-13
CN1402722A (zh) 2003-03-12
EP1244650A1 (fr) 2002-10-02
NO20022528L (no) 2002-05-28
EA200200616A1 (ru) 2002-10-31
HUP0204429A2 (hu) 2003-04-28
SK7402002A3 (en) 2002-11-06
IL149402A0 (en) 2002-11-10
ES2202206T3 (es) 2004-04-01
CO5251431A1 (es) 2003-02-28
PT1244650E (pt) 2003-11-28
AU2179001A (en) 2001-06-12
DE60003583D1 (de) 2003-07-31
KR20020058043A (ko) 2002-07-12

Similar Documents

Publication Publication Date Title
IL149402A0 (en) Arylamine derivatives and their use as anti-telomerase agent
DE60112974D1 (en) Carbolinderivate
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
WO2002096903A3 (fr) Derives chimiques et leur application comme agent antitelomerase
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
DE60216233D1 (en) Carbolinderivate
MXPA06000247A (es) Tetrahidro-1h-pirazolo[3,4-c]piridinas sustituidas composiciones que las contienen y su utilizacion.
GB9514473D0 (en) Chemical compounds
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
MXPA03002911A (es) Compuestos quimicos.
ATE231872T1 (de) Thiazolopyrimidinderivate
HK1076812A1 (en) Cyanoguanidine prodrugs
MXPA02012076A (es) Compuestos quimicos.
MXPA02012659A (es) Derivados de pirazindiona condensados.
HUP0500424A3 (en) Combination therapy for the treatment of cancer
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
MXPA03002909A (es) Compuestos quimicos.
GB0018951D0 (en) Novel compounds
GB0027705D0 (en) Novel compounds
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
MXPA02012472A (es) Compuestos quimicos.
HK1050533A1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer.
MXPA04005226A (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
ZA200408071B (en) Combination therapy for the treatment of cancer.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)